Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microtubule-associated protein tau (MAPT) is a neuronal protein that stabilizes microtubules. The cis-pT231 conformation, specifically tau phosphorylated at threonine 231 adopting a *cis* conformation at the peptide bond preceding proline, is implicated as an early driver of neurodegeneration and a potential therapeutic target for Alzheimer's disease and other tauopathies. This conformation impairs normal dephosphorylation processes, leading to its accumulation and subsequent pathological effects.
Inhibition of tau phosphorylation or aggregation, promotion of tau dephosphorylation, or clearance of pathological tau species.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microtubule-associated protein tau (cis-pT231 conformation) (None).